Tag: SIR 2025
WAVE trial update reports sustained 12-month survival benefit
Twelve-month results from the WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial show a statistically significant improvement in target lesion primary patency (TLPP) with the...